AstraZeneca (AZN) revenue
AstraZeneca (AZN) reported revenue of $58.74B in fiscal 2025 (the year ended December 31, 2025). That is 8.6% higher than the $54.07B of fiscal 2024. Figures as of 18 Nov 2026, 11:51 UTC, from Yahoo Finance.
Key facts
- Revenue, fiscal 2025
- $58.74B
- Change on fiscal 2024
- +8.6%
- Highest on record
- $58.74Bfiscal 2025
- Lowest on record
- $44.35Bfiscal 2022
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in USD. Figures, not advice.
AstraZeneca revenue, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was $58.74B in fiscal 2025 and the lowest $44.35B in fiscal 2022.
Revenue by fiscal year
AstraZeneca revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2025 | $58.74B | 8.6% up | |
| 2024 | $54.07B | 18.0% up | |
| 2023 | $45.81B | 3.3% up | |
| 2022 | $44.35B | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
AstraZeneca, figure by figure
- AstraZeneca market cap
- AstraZeneca earnings
- AstraZeneca earnings per share (EPS)
- AstraZeneca P/E ratio
- AstraZeneca P/S ratio
- AstraZeneca P/B ratio
- AstraZeneca free cash flow
- AstraZeneca operating margin
- AstraZeneca dividend
- AstraZeneca shares outstanding
- AstraZeneca total debt
- AstraZeneca cash on hand
- AstraZeneca total assets
- AstraZeneca return on equity (ROE)
- AstraZeneca return on invested capital (ROIC)
AstraZeneca (AZN) overview: price, valuation and scorecardAll health care companies by market value
AstraZeneca revenue: questions and answers
What is AstraZeneca's revenue?
AstraZeneca (AZN) reported revenue of $58.74B in fiscal 2025 (the year ended December 31, 2025). That is 8.6% higher than the $54.07B of fiscal 2024.
What are the highest and lowest revenue figures on record for AstraZeneca?
Across the 4 fiscal years on record (2022–2025), the highest was $58.74B in fiscal 2025 and the lowest $44.35B in fiscal 2022.
How is AstraZeneca's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For AstraZeneca it is on record here for 4 fiscal years, 2022 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “AstraZeneca (AZN) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/AZN/revenue
Underlying data: Yahoo Finance.